RESUMO

Rosacea is a chronic and inflammatory disease that primarily affects the skin, although more than half of cases also present with ocular symptoms ranging from blepharitis to conjunctivitis and keratitis. It represents a frequent reason for consultation with a psychosocial impact, affecting quality of life, and requires management involving ophthalmologists, dermatologists, and primary care physicians. For this paper, a search was conducted in several databases, including Medline, Embase, Cochrane, and Google Scholar, using the MeSH term "rosacea" in conjunction with other relevant keywords such as "ocular rosacea", "management", "treatment", and "guidelines". Available articles were reviewed. International and local guidelines recommend initiating the management of rosacea with lifestyle changes, including ocular hygiene and avoidance of triggers. Topical or oral treatment is recommended as the next step, with topical cyclosporine, topical azithromycin, topical tacrolimus, and oral doxycycline being the treatments most supported by evidence. Combination treatments are also recommended. Current management guidelines mainly focus on cutaneous manifestations, generating few guidelines on ophthalmologic treatment, and most recommendations are issued by experts. This work compares local and international treatment guidelines for rosacea, as well as other available medical literature, and suggests a practical and interdisciplinary treatment scheme for ocular involvement based on the reviewed bibliography.

Assuntos

RESUMO

La rosácea es una dermatosis crónica que se manifiesta clínicamente con eritema, telangiectasias, pápulas y pústulas en la parte central de la cara. Afecta, sobre todo, a los adultos y, en raras ocasiones, a los niños. La rosácea puede también presentar afección ocular y preceder, aparecer en forma simultánea o con posterioridad a las lesiones cutáneas; es mayor el riesgo de complicaciones oculares en los niños. La baja prevalencia de esta patología en la infancia origina demoras en el diagnóstico. Se presenta a un paciente de 1 año de edad con rosácea ocular y cutánea que desarrolló opacidades corneales con compromiso de la agudeza visual. Se destaca la importancia del diagnóstico y del tratamiento precoz para evitar el desarrollo de secuelas.

Rosacea is a chronic skin disease characterized by erythema, telangiectasia, papules and pustules in the central facial region. It most often affects adults and is rare in children. Rosacea can also present ocular involvement. Symptoms can precede cutaneous findings, appear simultaneously or after them, with a higher risk of ocular complications in children. Because of low prevalence of rosacea in childhood, the diagnosis is frequently delayed. We report a 1-year-old boy with ocular and cutaneous rosacea who developed corneal opacities and visual impairment. Early diagnosis and treatment is considerable to avoid sequels.

Assuntos

RESUMO

Rosacea is a chronic skin disease characterized by erythema, telangiectasia, papules and pustules in the central facial region. It most often affects adults and is rare in children. Rosacea can also present ocular involvement. Symptoms can precede cutaneous findings, appear simultaneously or after them, with a higher risk of ocular complications in children. Because of low prevalence of rosacea in childhood, the diagnosis is frequently delayed. We report a 1-year-old boy with ocular and cutaneous rosacea who developed corneal opacities and visual impairment. Early diagnosis and treatment is considerable to avoid sequels.

La rosácea es una dermatosis crónica que se manifiesta clínicamente con eritema, telangiectasias, pápulas y pústulas en la parte central de la cara. Afecta, sobre todo, a los adultos y, en raras ocasiones, a los niños. La rosácea puede también presentar afección ocular y preceder, aparecer en forma simultánea o con posterioridad a las lesiones cutáneas; es mayor el riesgo de complicaciones oculares en los niños. La baja prevalencia de esta patología en la infancia origina demoras en el diagnóstico. Se presenta a un paciente de 1 año de edad con rosácea ocular y cutánea que desarrolló opacidades corneales con compromiso de la agudeza visual. Se destaca la importancia del diagnóstico y del tratamiento precoz para evitar el desarrollo de secuelas.

Assuntos

RESUMO

AIMS: The purpose of this paper was to determine the lacrimal concentration of IL-1α and MMP-9 in patients with active ocular rosacea before and after systemic treatment with azithromycin or doxycycline. METHODS: After 4 weeks of therapy with azithromycin (500 mg/day, 3 days a week PO) or doxycycline (200 mg/day PO), lacrimal samples were analyzed using an enzyme-linked immunosorbent assay multiplex. RESULTS: There was a significant difference between baseline IL-1α (37.9 pg/mL) and MMP-9 (26.7 ng/mL) in rosacea eyes compared to controls (0.001 pg/mL for IL-1α and 0.2 ng/mL for MMP-9) (p < 0.001). IL-1α decreased from 47.0 pg/mL before azithromycin to 23.5 pg/mL after treatment (p = 0.024), but not after doxycycline therapy. On the contrary, baseline MMP-9 tear levels (10.28 ng/mL) decreased after treatment (8.36 pg/mL) with doxycycline (p = 0.054) but not with azithromycin. There was a strong clinical correlation of higher baseline IL-1α tear levels between patients who responded to doxycycline therapy and those who failed (p = 0.043). Patients unresponsive to azithromycin had significantly higher baseline MMP-9 levels than those with doxycycline (p = 0.040). CONCLUSIONS: While IL-1α levels decreased after azithromycin therapy, MMP-9 did so after doxycycline treatment. Baseline cytokine tear levels tend to be markedly elevated in patients with antibiotic failure, suggesting their potential role as therapeutic biomarkers for the disease.

Assuntos